All In Biotech

Drug Trial Radar · NCT07239414

Bempedoic Acid Versus Statins in Primary-Prevention Patients With Suboptimal Statin Adherence: Effects on LDL-C Reduction and Tolerability

Last checked: Nov 20, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 690 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

690

Planned (sponsor's estimate)

Start

Nov 10, 2025

Primary completion

Nov 10, 2026

Study completion Feb 21, 2027

Sponsor

Lead sponsor
Sohaib AshrafAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Bempedoic acid is an oral, non-statin LDL-cholesterol (LDL-C) lowering agent that inhibits ATP citrate lyase (ACL), upstream of HMG-CoA reductase (the enzyme inhibited by statins). MDPI +1 In patients with hypercholesterolemia who are unable to tolerate statins, or have sub-optimal statin adherence/tolerance, bempedoic acid has been shown to reduce LDL-C by \~20-30% (monotherapy) and more when added to other therapies (e.g., ezetimibe) (≈30-40%). PubMed * 2 medicinejournal.in * 2 In the large primary-prevention subgroup of the trial CLEAR Outcomes (statin-intolerant patients without prior cardiovascular event), bempedoic acid (180 mg daily) lowered LDL-C by \~21.3% and hs-CRP by \~21.5%. It also was associated with a significant reduction in major adverse cardiovascular events (MACE): hazard ratio 0.70 (95% CI 0.55-0.89) versus placebo over \~40 months. PubMed +1 Regarding tolerability: muscle-related adverse events appear lower compared to statins (because bempedoic acid is activated only in the liver, not in skeletal muscle) and it appears generally well tolerated, but there are signals of increased uric acid/gout, elevated hepatic enzymes, and creatinine/renal effects. MDPI +1 Comparative cardiovascular benefit (when normalized per unit LDL-C reduction) suggests that bempedoic acid may yield similar relative risk reductions as statins, though absolute LDL-C lowering is less.

Conditions

  • Cardiovascular

Interventions

  • Bempedoic Acid 180 MG Oral TabletDrug

    BA 180mg OD

  • Rosuvastatin 5 mgDrug

    rosuvastatin 5mg HS

  • PlaceboDrug

    Placebo given OD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in LDL-CTime frame: 6 months
  2. Composite adherence/tolerability endpoint:Time frame: 6 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.